CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net (loss) income	$ (10,936)	$ 117,699	$ 210,166
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	23,847	24,935	30,901
Non-cash compensation	29,024	16,560	23,809
Amortization and impairment of operating lease right of use assets	33,996	46,029	40,364
Loss (gain) on disposal of property and equipment	319	519	(124)
Gain on equity method investments	0	0	(31,098)
Deferred income taxes	20,655	23,377	44,582
Loss on personal care divestiture	2,186	0	0
Merger termination fee	106,000	0	0
Equity in (earnings) loss from equity method investments	(10,760)	45	(4,949)
Amortization of deferred debt issuance costs	991	991	917
Return on equity method investments	5,073	5,163	5,343
Investment impairment	0	3,009	0
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(26,727)	(14,230)	(18,030)
Other current assets	(6,638)	(3,525)	(12,202)
Operating lease right of use assets	(3,786)	(3,242)	(3,060)
Other assets	189	438	(1,017)
Accounts payable	(15,816)	4,894	(4,353)
Accrued expenses	23,694	(39,382)	(26,915)
Other long-term obligations	(3,390)	(8,822)	(28,796)
Operating lease liabilities	(30,733)	(41,175)	(36,645)
Net cash provided by operating activities	137,188	133,283	188,893
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	54	252	135
Proceeds from the sale of property and equipment	136	66	144
Purchases of property and equipment	(5,620)	(6,165)	(6,302)
Investments in technology assets	(7,093)	(1,050)	(419)
Investment in equity method investee	0	(637)	(200)
Purchase of cost method investment	0	(15,000)	(5,000)
Return of investment	150	0	0
Proceeds from personal care divestiture	47,787	0	0
Acquisitions of businesses, net of cash acquired	(350)	(71,952)	(269,965)
Net cash provided by (used in) investing activities	35,064	(94,486)	(281,607)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	100	2,304	2,054
Proceeds from issuance of stock to employee stock purchase plan	2,602	3,848	3,968
Shares withheld to pay taxes on non-cash compensation	(6,529)	(7,981)	(16,898)
Noncontrolling interest contributions	1,452	3,501	250
Noncontrolling interest distributions	(1,873)	(1,561)	(1,747)
Proceeds from sale of noncontrolling interest	0	5,817	0
Proceeds from borrowings under term loan	0	0	290,312
Proceeds from borrowings under revolving line of credit	23,000	534,500	500,700
Repayments of borrowings under revolving line of credit	(23,000)	(534,500)	(551,700)
Principal payments of long-term obligations	(76,013)	(13,296)	(9,143)
Debt issuance costs	0	0	(2,792)
Provider relief fund advance	0	0	(60,000)
Purchase of company stock	0	(17,351)	(99,878)
Payment of accrued contingent consideration	(6,461)	(5,714)	0
Purchase of noncontrolling interest	(800)	0	0
Net cash (used in) provided by financing activities	(87,522)	(30,433)	55,126
Net increase (decrease) in cash, cash equivalents and restricted cash	84,730	8,364	(37,588)
Cash, cash equivalents and restricted cash at beginning of period	54,133	45,769	83,357
Cash, cash equivalents and restricted cash at end of period	138,863	54,133	45,769
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	29,766	14,939	5,291
Cash Paid For Infinity ZPIC Interest	0	12,755	0
Cash paid for income taxes, net of refunds received	29,127	24,013	34,097
Accrued contingent consideration	0	19,195	0
Noncontrolling interest contribution	$ 0	$ 8,900	$ 0